Las Vegas, NV -- (SBWIRE) -- 12/06/2013 -- EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more .EquityObserver.com issues a special report on the following stocks: Amarin Corporation plc (ADR) (NASDAQ:AMRN), Idera Pharmaceuticals Inc (NASDAQ:IDRA), Delcath Systems, Inc. (NASDAQ:DCTH), , Oculus Innovative Sciences, Inc. (NASDAQ:OCLS)
Amarin Corporation plc (ADR) (NASDAQ:AMRN) managed to keep its fall at -6.70% on below -normal volume of 4.16M shares. The stock settled at $1.81 after floating in a range of $1.80 to $1.96. Its latest price has reached market capitalization of $312.47 million. Its 52-week range has been $1.36 to $12.65. Amarin Corporation plc (Amarin) is a late-stage biopharmaceutical -company with expertise in lipid science focused on the treatment of cardiovascular disease. The Company’s product candidate is AMR101, an ultra-pure omega-3 fatty acid. It is developing AMR101 for the treatment of patients with high triglyceride levels, or hypertriglyceridemia. In September 2011, it filed a New Drug Application (NDA), with the United States Food and Drug Administration (FDA).
Has AMRN Found The Bottom and Ready To Move Up? Find Out Here
Idera Pharmaceuticals Inc (NASDAQ:IDRA) traded up on a volume of 4.11 million, higher than its standard daily volume. Shares have gained 6.12% to $2.60. Over the last twelve months, the stock has gained 251.35% and faced a worst price of $0.19. Idera Pharmaceuticals, Inc. is a clinical-stage biotechnology company engaged in the discovery and development of novel synthetic deoxyribonucleic acid (DNA) - and ribonucleic acid (RNA) - based drug candidates. The Company is developing drug candidates that are designed to modulate immune responses mediated through Toll-like Receptors (TLRs). It is also evaluating gene silencing oligonucleotides (GSOs), which inhibit the production of disease-associated proteins by targeting RNA.
For How Long IDRA’s Gloss will Attract Investors? Find out via this report
Delcath Systems, Inc. (NASDAQ:DCTH) settled -8.17% lower at $0.275 on above-normal volume of 4.01M shares during the last trading day. The stock has its 12-month high at $2.19 and 52-week low price was $0.27. It traded in a range of $0.27 to $0.30 during the last trading day. Delcath Systems, Inc. (Delcath) is a development-stage, specialty pharmaceutical and medical device company, focused on oncology, initially cancers in the liver. Delcath focuses on the development and clinical study of the Delcath chemosaturation system.
Will DCTH Get Buyers Even After The Recent Rally? Find Out Here
In the last trading session, Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) was down high volume, trading at a volume of 3.70M versus its average daily volume of 643,908.00 shares. At $4.17, the stock has attained market capitalization of 27.71 million. Oculus Innovative Sciences, Inc. is a global healthcare company that designs, produces, and markets prescription and non-prescription products in over 20 countries.The Company’s focus is on the commercialization of its technology platform called Microcyn Technology.
Why Should Investors Buy OCLS After the Recent Fall? Just Go Here and Find Out
About Equity Observer
Equity Observer delivers intra-day insights into the equities, tech and investment world. The website is a window into what’s going on in the business world and why.
EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.
The disclaimer is to be read and fully understood before using our site, or joining our email list.
http://www.equityobserver.com/ has a no tolerance spam policy; we will not sell or re-distribute your email to any 3rd party. A If applicable, please also unsubscribe from the newsletter using the link at the bottom of the email if you no longer wish to receive our emails. We only send our newsletters to opt-in members.
PLEASE NOTE WELL: The http://www.equityobserver.com/
Employees and contributors are NOT registered as an Investment Adviser in any jurisdiction whatsoever.
Read Full Disclaimer at: http://www.equityobserver.com/
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)